Expert Q&A - Renal and Urology News

If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Expert Q&A Interviews

Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD

Delicia Honen Yard May 15, 2012

Several new drugs have become available for treating advanced prostate cancer in the past year and a half. E. David Crawford, MD, head of urologic oncology at University of Colorado (UC) Hospital and an investigator at the UC Cancer Center, both in Aurora, and UC colleague Thomas W. Flaig, MD, recently published a review of these agents. Dr. Crawford talks to Renal & Urology News about the possible ways in which these drugs might be used.

With ESAs, Let Your Patient Be Your Guide: An Interview with Alan S. Kliger, MD

Delicia Honen Yard April 11, 2012

When using erythropoiesis-stimulating agents (ESAs) to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target and more on improving patient-perceived quality of life in such areas as fatigue, weakness, and shortness of breath, advises Alan S. Kliger, MD, Chief Medical Officer and Chief Quality Officer for the Saint Raphael Healthcare System in New Haven, Conn.

The Case for Brachytherapy: An Interview with Michael F. Sarosdy, MD

Delicia Honen Yard March 14, 2012

Having performed more than 1,200 brachytherapy treatments since 1996 and conducting research in this field, urologic oncologist Michael F. Sarosdy, MD, founder of South Texas Urology & Urologic Oncology, in San Antonio, is convinced that this is a far better choice than surgery for most men with prostate cancer, regardless of the patient's age or tumor characteristics.

Potential of FGF23 Yet to Be Unleashed An Interview with Orlando M. Gutirrez, MD

Potential of FGF-23 Yet to Be Unleashed: An Interview with Orlando M. Gutiérrez, MD

Delicia Honen Yard February 15, 2012

Although it does not yet have a place in everyday practice, fibroblast growth factor 23 (FGF-23) may one day be an important marker of and therapeutic target for very early-stage chronic kidney disease for the clinical nephrologist. Orlando M. Gutiérrez, MD, Assistant Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham, has studied in depth this bone-derived hormone, which regulates phosphorus and vitamin D.

The Lowdown on HIFU: An Interview with David Y.T. Chen, MD, FACS

Delicia Honen Yard January 13, 2012

Although high-intensity focused ultrasound (HIFU) has not yet been approved in the United States for the treatment of prostate cancer, a growing number of the nation's urologists are offering this noninvasive surgical procedure at centers located outside the country. Renal & Urology News asked urologic oncologist David Y.T. Chen, MD, FACS, of Fox Chase Cancer Center in Philadelphia, about his impressions of HIFU as an investigator in a trial featuring the treatment.

The Case for Neonatal Male Circumcision: An Interview with Aaron Tobian, MD, PhD

Delicia Honen Yard December 01, 2011

Less than a decade ago, Aaron Tobian, MD, PhD, would not have been a proponent of male circumcision. But now the benefits of this procedure are undeniable to the Johns Hopkins Center for Global Health pathologist, who has studied the matter extensively both in the United States and in Uganda. Dr. Tobian spoke with Renal & Urology News hours after returning from his most recent trip to sub-Saharan Africa.

Better Lithotripsy On the Horizon: An Interview with James E. Lingeman, MD

Delicia Honen Yard November 01, 2011

A leading authority on kidney stone disease, James E. Lingeman, MD, of Indiana University Health, updates Renal & Urology News on the state of urinary stone treatment, including a possible rebirth of extracorporeal shock wave lithotripsy and the pursuit of the "holy grail" in flexible ureteroscopy.

Avanafil and PDE-5 Inhibitors: An Interview with Wayne J. G. Hellstrom, MD, FACS

Jody A. Charnow October 15, 2011

Dr. Hellstrom, Professor of Urology and Chief of Andrology at Tulane University School of Medicine in New Orleans, is one of the principal investigators involved in studies of avanafil, an investigational phosphodiesterase-5 (PDE-5) inhibitor that in phase 3 trials has demonstrated efficacy and potential advantages over other PDE-5 inhibitors. In an interview with Renal & Urology News, he discusses avanafil and PDE-5 inhibitors in general.

HIV-Positive Organ Donors for HIV-Positive Recipients: An Interview with Dorry Segev, MD, PhD

Jody A. Charnow October 01, 2011

Human immunodeficiency virus (HIV) is no longer a contraindication to transplantation, contends Dorry Segev, MD, PhD. The Associate Professor of Surgery and Epidemiology and Director of Clinical Research at Johns Hopkins Comprehensive Transplant Center in Baltimore tells Renal & Urology News that kidney transplantation is a particularly strong contender for consideration in this matter.

Issues in Hypertension: An Interview with George Bakris, MD

Jody A. Charnow September 01, 2011

George Bakris, MD, Professor of Medicine and Director of the Hypertensive Diseases Center at the University of Chicago Medical Center, is an internationally recognized hypertension expert who specializes in complicated or refractory cases. He spoke with Renal & Urology News about various aspects of treating hypertension in patients with chronic kidney disease.

The Robotic Prostatectomy: An Interview with Mani Menon, MD

Jody A. Charnow August 01, 2011

Mani Menon, MD, is a urologist and Director of the Vattikuti Institute at Henry Ford Hospital in Detroit. Dr. Menon is a pioneer in the development of robotic surgery, especially the robotic prostatectomy. In this interview, Dr. Menon discusses the place of robotic prostatectomy in the treatment of localized prostate cancer.

Newsletters

Latest News
Latest CME
Ongoing Clinical Trials
Conference Highlights
Expert Q&A

Directories

Renal & Urology News has three directories for our users, including buyer's guides for products and services in urology and nephrology as well as a state-by-state listing of dialysis centers.

On The Forefront

Sickle Cell Trait and Medullary Renal Carcinoma

A 55-year-old Caucasian woman initially presented to one of Cleveland Clinic's regional outpatient urology clinics with gross hematuria and an obstructing right ureteral stone.

Renal Nutrition Update

High Protein Intake May Elevate Levels of Advanced Glycation End Products

Advanced glycation end products (AGEs) are byproducts of non-enzymatic chemical reactions between sugars and amino acids, lipids, or DNA. A wide range of molecules fall into this category.